Maalox plus Benadryl
ApprovedSmall molecule
Maalox plus Benadryl is one of 11 small molecule programs targeting Aphthous Ulcer. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Aphthous Ulcer
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Benadryl
PParkedale
Approved
Advil
KKenvue Brands
Approved
Thalomid
Bristol-Myers SquibbPhase 2
Verazinc
FFakultas Kedokteran Universitas Indonesia
Phase 2
Maalox plus Benadryl
TThe University of Texas Health Science Center, Houston
Approved
Peridex
MMedline Industries
Preclinical
Coenzyme Q10
MMclean Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Maalox plus Benadryl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details